Lyra Therapeutics Valuation
| LYRA Stock | USD 0.19 0.01 5.56% |
Lyra Therapeutics seems to be undervalued based on Macroaxis valuation methodology. Our model forecasts the value of Lyra Therapeutics from analyzing the firm fundamentals such as Shares Outstanding of 65.46 M, return on equity of -1.86, and Operating Margin of (49.43) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lyra Therapeutics' valuation include:
Price Book 0.6 | Enterprise Value -3.9 M | Enterprise Value Ebitda 0.6593 | Price Sales 8.4103 | Enterprise Value Revenue 153.7687 |
Undervalued
Today
Please note that Lyra Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Lyra Therapeutics is based on 3 months time horizon. Increasing Lyra Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lyra Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lyra Stock. However, Lyra Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.19 | Real 3.39 | Target 13.0 | Hype 0.18 | Naive 0.14 |
The real value of Lyra Stock, also known as its intrinsic value, is the underlying worth of Lyra Therapeutics Company, which is reflected in its stock price. It is based on Lyra Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Lyra Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Lyra Therapeutics helps investors to forecast how Lyra stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lyra Therapeutics more accurately as focusing exclusively on Lyra Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lyra Therapeutics' intrinsic value based on its ongoing forecasts of Lyra Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lyra Therapeutics' closest peers. If more than one evaluation category is relevant for Lyra Therapeutics we suggest using both methods to arrive at a better estimate.
Lyra Therapeutics Cash |
|
Lyra Valuation Trend
Comparing Lyra Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Lyra Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Lyra Therapeutics Total Value Analysis
Lyra Therapeutics is now projected to have valuation of (3.93 M) with market capitalization of 12.37 M, debt of 26.88 M, and cash on hands of 120.67 M. The negative valuation of Lyra Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Lyra Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(3.93 M) | 12.37 M | 26.88 M | 120.67 M |
Lyra Therapeutics Investor Information
About 59.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.6. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lyra Therapeutics has Price/Earnings To Growth (PEG) ratio of 1.61. The entity recorded a loss per share of 1.49. The firm had not issued any dividends in recent years. Based on the key indicators related to Lyra Therapeutics' liquidity, profitability, solvency, and operating efficiency, Lyra Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Lyra Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lyra Therapeutics has an asset utilization ratio of 1.09 percent. This suggests that the Company is making $0.0109 for each dollar of assets. An increasing asset utilization means that Lyra Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Lyra Therapeutics Ownership Allocation
Lyra Therapeutics maintains a total of 65.46 Million outstanding shares. Over half of Lyra Therapeutics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Lyra Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1.56 M. Net Loss for the year was (62.68 M) with loss before overhead, payroll, taxes, and interest of (34.23 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Lyra Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Lyra Therapeutics and how it compares across the competition.
About Lyra Therapeutics Valuation
The stock valuation mechanism determines Lyra Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Lyra Therapeutics. We calculate exposure to Lyra Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lyra Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -46.5 M | -44.1 M | |
| Pretax Profit Margin | (40.19) | (42.20) | |
| Operating Profit Margin | (43.08) | (45.23) | |
| Net Loss | (40.23) | (42.24) | |
| Gross Profit Margin | (29.83) | (28.34) |
Lyra Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 49.8 M |
Lyra Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Lyra Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Lyra we look at many different elements of the entity such as Lyra's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lyra Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lyra Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lyra Therapeutics' worth.Complementary Tools for Lyra Stock analysis
When running Lyra Therapeutics' price analysis, check to measure Lyra Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyra Therapeutics is operating at the current time. Most of Lyra Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lyra Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyra Therapeutics' price. Additionally, you may evaluate how the addition of Lyra Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |